Pre-launch study type
- Standard of care treatments and outcomes in populations defined by new biomarkers (re-testing capabilities)
- Characterisation of subgroups of patients with poor outcomes based on molecular and clinical features
Launch and post-launch study type
- Resistance mechanisms of patients with disease progression at all lines of treatment